glp 1 visceral fat How Do GLP-1 Shots Change Your Body Composition? Myths & Facts: GLP-1 Drugs

and generic manufacturers positioning for biosimilar competition from 2031 onward

Moving from insulin to GLP-1 A patient on basal insulin whose Type 2 diabetes is relatively well controlled might transition to a GLP-1 agonist if they are gaining excessive weight on insulin, want to simplify their regimen, have developed cardiovascular risk factors that would benefit from GLP-1 protection, or have adequate remaining beta cell function

Same-day surgery workflows may identify GLP-1 use too late for ideal planning

Intermittent fasting may not be appropriate for everyone, especially people with chronic health conditions, diabetes, or medication-related concerns

The Lancet Haematology

This menopause-related visceral adiposity carries substantially higher cardiometabolic risk including increased likelihood of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, hypertension, and metabolic syndrome